

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: BioMark Diagnostics Inc. (the "Issuer").

Trading Symbol: BUX

Number of Outstanding Listed Securities: 77,974,229

Date: December 2nd, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued its business of developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor, and assess treatment for cancer early, accurately and cost effectively.

2. Provide a general overview and discussion of the activities of management.
 - **Even though COVID-19 pandemic management measures intensify along with aggressive vaccination, testing and vaccine verification programs being implemented, there is now heightened awareness of the most recent Omnicore variant that has a high infection rate. The company remains hopeful but vigilant. Financial, operational and recovery measures instituted by the management team aided in sustaining business viability over the past 18 months and the company intends to navigate potential any short-term impact of this pandemic resurgence.**
 - **BioMark is fine tuning its instrument calibration with vendors for its Quebec based lab facilities. Technician training and quality management system is being designed as the company prepares for the verification and validation of the samples related to the early-stage lung cancer detection study (funded under Medteq sponsored research). The biological samples are being shipped for analysis.**
 - **On November 8th, 2021, BioMark announced that the diagnostic and therapeutic capabilities of its SSAT cancer marker were featured in virtual posted presentation at the sixth biennial Canadian Cancer Research Conference that was to be held virtually from Nov 8-11, 2021.**
 - **On November 10th, 2021, BioMark announced that it recognized and wanted to raise awareness of the challenges that come from a diagnosis of lung cancer. BioMark posted relevant short articles related to this fatal disease in different social media sites during November. The campaign aims to encourage both men and women**

to know their risks for lung cancer and to consider annual screening to gain an advantage on the disease through earlier diagnosis.

- On November 16, 2021, BioMark announced that its Quebec-based subsidiary, BioMark Diagnostic Solutions Inc (“BDS”), received advisory services and funding of up to CAD \$169,550 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support research and development of its liquid biopsy assay for the early detection and screening of lung cancer.
- On November 25, 2021, BioMark reported its operational update for the second quarter ended September 30, 2021. The Company also announced that it extended the warrant exercise term on a continuing effort to improve corporate value for its shareholders.
- On November 30, 2021, BioMark announced its Quebec-based wholly owned subsidiary BioMark Diagnostic Solutions Inc. (“BDS”) will be participating in a sponsored research project which aims to enhance the efficiency of current lung cancer screening programs and facilitate the identification of individuals who would benefit from more invasive tests, such as lung biopsy. Total funding for this collaborative research project is about \$3.5 million and is made possible in part with the financial support of the Ministère de l’Économie et de l’Innovation (MEI) as part of CQDM’s SynergiQC program and from an exceptional donation made by Mr. Normand Lord to the IUCPQ Foundation.
- Preliminary data analysis on an early breast cancer metabolic panel looks very promising. The study involved 280 samples with emphasis on early stage (I and II). Detailed statistical analysis is underway at TMIC. Results are expected by mid-December with patents being filed shortly thereafter.
- Discussions continues with various financial institutions and government agencies to secure non-dilutive funding, favourable loans and equity investments to accelerate the commercialization of its early lung cancer liquid biopsy franchise and to purchase additional equipment to support operation and expansion in Quebec.

- **The company is re-establishing its US expansion plans. Business partnership activities are being explored and new potential clinical trial institutions have been identified. Meetings with senior key team members have been booked for later in December.**

About the Canadian Cancer Research Alliance Conference

The Canadian Cancer Research Alliance is an alliance of organizations that work strategically to co-ordinate and collaborate on cancer research conducted in Canada to support cancer discoveries that uncovers factors which may cause cancer and the development of treatments to improve patient and survivor outcomes. This year, the sixth biennial Canadian Cancer Research Conference (CCRC) will be a fully virtual, online experience taking place from November 8 to 11, 2021. The four half-day virtual events will bring together the Canadian cancer research community for an agenda spanning the research spectrum. The conference is an ideal opportunity for researchers, trainees, clinicians, decision-makers and patients to hear the latest developments in Canadian cancer research, and network across research disciplines.

About CQDM

CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that will accelerate the discovery and development of safer and more effective drugs. We bring together world-leading pharmaceutical organizations, several Canadian biotech companies, the best researchers from the public and private sectors, as well as the Canadian and Quebec governments. CQDM's collaborative approach bridges the funding gap needed to drive innovation across the academic and private sectors, especially where early-stage research is concerned. For more information – Website: www.cqdm.org, LinkedIn et Twitter.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not applicable.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

The Issuer continues to file trademark and patents in specific jurisdictions for all its patents. Review of the filings and opinions from patent offices are being reviewed as needed.

10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable.

FORM 7 – MONTHLY PROGRESS REPORT

January 2015

Page 5

11. Report on any labour disputes and resolutions of those disputes if applicable.
Not applicable.
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
Not applicable.
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
Not applicable.
14. Provide details of any securities issued and options or warrants granted.
The Company amended the term of 1,15,579 non-broker warrants (the "Warrants") issued in relation to a private placement financing that closed on December 13, 2019. The Warrants extended their term by one year such that the warrants will be exercisable until December 13, 2022, at an exercise price per share of C\$0.45. All other terms of the warrants will remain unchanged.
15. Provide details of any loans to or by Related Persons.
Not applicable.
16. Provide details of any changes in directors, officers, or committee members.
Not applicable.
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.
The trends and risks which are likely to impact the Issuer are discussed in the Form 51-102F1 Management's Discussion & Analysis Annual Report for the Year Ended March 31, 2021.

FORM 7 – MONTHLY PROGRESS REPORT

January 2015

Page 6

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there where is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated December 2nd, 2021.

Rashid Ahmed Maula Bux
Name of Director or Senior Officer

"Rashid Ahmed Maula Bux"
Signature

President & CEO
Official Capacity

Issuer Details Name of Issuer BioMark Diagnostics Inc.	For Month End November, 2021	Date of Report YY/MM/DD 2021/12/02
Issuer Address 130 - 3851 Shell Road		
City/Province/Postal Code Richmond, BC, V6X 2W2	Issuer Fax No. N/A	Issuer Telephone No. (604) 370-0779
Contact Name Rashid Ahmed Bux	Contact Position CEO	Contact Telephone No. (604) 370-0779
Contact Email Address info@biomarkdiagnostics.com	Web Site Address www.biomarkdiagnostics.com	

FORM 7 – MONTHLY PROGRESS REPORT

January 2015